The estimated Net Worth of John W. Crowley is at least $14.4 Milione dollars as of 16 January 2018. John Crowley owns over 3,866 units of Lantheus Inc stock worth over $14,135,979 and over the last 9 years John sold LNTH stock worth over $215,288.
John has made over 2 trades of the Lantheus Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently John sold 3,866 units of LNTH stock worth $90,928 on 16 January 2018.
The largest trade John's ever made was selling 6,755 units of Lantheus Inc stock on 13 October 2017 worth over $124,360. On average, John trades about 625 units every 6 days since 2015. As of 16 January 2018 John still owns at least 138,656 units of Lantheus Inc stock.
You can see the complete history of John Crowley stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862.
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av... e Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
Lantheus Inc executives and other stock owners filed with the SEC include: